

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: ZUCKER-FRANKLIN, et al.
 Serial No.: 09/543,782
 Filed: April 6, 2000
 For: ASSAYS FOR HUMAN T-CELL...

Art Unit: 1655
 Examiner: C. WILDER
 Washington, D.C.
 Atty.'s Docket: ZUCKER-FRANKLIN=1A
 Date: April 9, 2001

RECEIVED

APR 16 2001

TECH CENTER 1600 2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:

Transmitted herewith is an [XX] Amendment [] _____
 in the above-identified application.

- [] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
 [] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
 [] No additional fee is required.

The fee has been calculated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	Small Entity	Other Than a Small Entity
Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra	Rate	Additional Fee
10	20	=	x 9	\$
Indep. 2	3	=	x 40	\$
First Presentation of Multiple Dependent Claim			135	\$
TOTAL ADDITIONAL CLAIMS FEE				\$
				Total \$

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
 ** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
 *** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.
 The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col.1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time
 If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[XX] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- [] First - \$ 55.00
 [XX] Second - \$195.00
 [] Third - \$445.00
 [] Fourth - \$695.00

Other Than Small Entity

Response Filed Within

- [] First - \$ 110.00
 [] Second - \$ 390.00
 [] Third - \$ 890.00
 [] Fourth - \$1390.00

[] Less fees (\$) already paid for months extension of time on

[] Please charge my Deposit Account No. 02-4035 in the amount of \$ _____. A duplicate copy of this sheet is attached.

[] A check in the amount of \$ _____ is attached (check no. _____).

[XX] Credit Card Payment Form, PTO-2038, authorizing payment in the amount of \$ 195.00 is attached.
 [XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

By: Anne M. Kornbau
 Registration No. 25,884

AMK:nmp

09/543,782-ZUCKER-FRANKLIN-ET AL-1001-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: ZUCKER-FRANKLIN=1A

In re Application of:

ZUCKER-FRANKLIN, et al.

Serial No.: 09/543,782

Filed: April 6, 2000

For: ASSAYS FOR HUMAN T-CELL
LYMPHOTROPIC VIRUS
TYPES I AND II

) Art Unit: 1655

) Examiner: C. WILDER

) Washington D.C.

) April 9, 2001

RECEIVED

APR 16 2001

TECH CENTER 1600 2900



AMENDMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

In response to the Office Action of November 13, 2000,
for which a two month extension of time to respond is hereby
requested, please enter the following amendment:

IN THE SPECIFICATION

Submitted herewith is an Abstract of the Disclosure
on a separate sheet of paper.

Adjustment date: 04/13/2001 JADD01
04/10/2001 JADD01 00000055 09543728
01 FC:216 -195.00 0P

IN THE CLAIMS

Please amend claim 1 as follows:

1. (Amended) A method of screening blood donors or
potential blood donors for carriers of diseases or conditions
related to HTLV-I and/or HTLV-II infection, comprising:

wherein a positive test indicates the presence of:

(a) HTLV-I and/or HTLV-II Tax protein;

(b) DNA which encodes the HTLV-I Tax protein and/or

(c) antibodies specific to the HTLV-I Tax protein

and/or antibodies specific to the HTLV-II Tax protein; and

determining that the donor is a carrier of a disease

04/10/2001 JADD01 00000055 09543728

01 FC:216

195.00 0P

04/13/2001 JADD01 00000006 09543782

01 FC:216

195.00 0P